Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
University of Chicago
mi
from
Chicago, IL
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Status: Archived
University of Chicago
mi
from
Chicago, IL
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Children's Doctor
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Children's Doctor
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Emory University
mi
from
Atlanta, GA
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
A Study for Leukemia Patients With Life-Threatening Infections
Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study for Leukemia Patients With Life-Threatening Infections
Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840003
mi
from
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840003
mi
from
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840002
mi
from
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840002
mi
from
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840001
mi
from
Houston, TX
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840001
mi
from
Houston, TX
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
Rady Children's Hospital
mi
from
San Diego, CA
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Archived
Updated: 1/1/1970
Rady Children's Hospital
mi
from
San Diego, CA
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Status: Archived
Northwestern University
mi
from
Chicago, IL
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
St. Vincent's Hospital
mi
from
Los Angeles, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St. Vincent's Hospital
mi
from
Los Angeles, CA
Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk
A Biologic Correlates Study for "A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk
A Biologic Correlates Study for "A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
mi
from
Seattle, WA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Seattle, WA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Portland Cancer Center
mi
from
Portland, OR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Portland Cancer Center
mi
from
Portland, OR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Ft. Smith, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Ft. Smith, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Peninsula Medical Center
mi
from
Burlingame, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Peninsula Medical Center
mi
from
Burlingame, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
mi
from
Marysville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
mi
from
Marysville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Cancer Center at Roseville Medical Center
mi
from
Roseville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center at Roseville Medical Center
mi
from
Roseville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Cancer Center
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
California Pacific Medical Center - California Campus
mi
from
San Francisco, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center - California Campus
mi
from
San Francisco, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Health - Western Division Cancer Research Group
mi
from
San Rafael, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Health - Western Division Cancer Research Group
mi
from
San Rafael, CA